实质性突破！应和脑科学介入脑机接口长期动物数据惊艳亮相IEEE NER 2025

Core Viewpoint - The article highlights the significant breakthrough achieved by Shenzhen Amygdala Neuro in the field of brain-computer interfaces (BCI) with the development of an endovascular electrode array that demonstrates long-term stability in large animal models, paving the way for clinical applications of BCI technology [2][12]. Group 1: Research Findings - The study successfully validated a mechanical architecture of an endovascular electrode array in large animal models, demonstrating nearly six months of dual-mode (recording + stimulation) functional stability [3][12]. - The research involved three adult sheep, where the electrode array was precisely implanted in the superior sagittal sinus, covering the motor cortex area, and monitored for nearly six months [4][12]. - Electrochemical impedance spectroscopy (EIS) measurements indicated good long-term electrochemical stability of the endovascular electrode in a vascular environment, with initial impedance around 1188 Ω, increasing to 2333 Ω by day 31, and then stabilizing at 1365 Ω by day 140 [6][12]. Group 2: Signal Recording and Stimulation - The study utilized the Apollo-I system to collect electrocorticography (ECoG) signals, revealing stable recordings of typical brain rhythms across various frequency bands (θ, α, β, low γ) [9][12]. - The stimulation results indicated that the threshold for eliciting body responses increased over time, with early responses at 1-2 mA (68% success rate) dropping to 3-5 mA (50% success rate) by day 112 [10][12]. - The electrode's ability to stimulate and record over a long duration supports the feasibility of using endovascular electrode arrays for neural modulation in clinical settings [11][12]. Group 3: Competitive Landscape - Synchron recently completed a $200 million Series D funding round, marking one of the largest single-round financings in the BCI field, which has drawn significant attention from the medical device industry [12]. - The article contrasts Amygdala Neuro's approach with Synchron's Stentrode™, highlighting the use of a mechanically woven nitinol stent and platinum-iridium microelectrodes, which offers advantages in terms of cost and flexibility for domestic BCI device development [12][13]. Group 4: Company Mission and Vision - Amygdala Neuro is committed to advancing brain-computer interface and neural modulation technologies, aiming to become a leading provider of solutions in neuroscience and high-reliability product manufacturing [16].